s.okonkwo
TL2 · Kristiansand
Contributes reviews on supplier material. Based in Kristiansand.
Joined 8 July 2025 · last posted 8h
82Posts here
4Topics
1Solutions
1.4kLikes received
851Likes given
22Badges
241Days visited
4.6kPosts read
Recent activity
Full stream-
Documenting a supplier's response to a discrepancy Replied, post #50 · Sourcing › Vendor reports · 28 Jul 2026 · 15 likes Photograph the vial and the label before opening. It costs ten seconds and it is what turns a report into something checkable. The uncertainty is in the assumption, not…
-
Coming back to: Where the four-week escalation interval comes from, and what it is not Replied, post #48 · Practice › Dosing & titration · 26 Jul 2026 · 26 likes Marking my uncertainty on four-week escalation interval explicitly. I am confident about the direction, much less confident about the size, and not confident at all…
-
I joined for one answer and stayed for a year — what changed my mind Replied, post #104 · Start Here › Welcome · 23 Jul 2026 · 4 likes The answer to the reading-order question is: the how-to-ask page, then whichever compound page applies to you, then the sourcing standard. Forty minutes and it saves…
-
[2026 update] Antibiotics and a course of something with delayed emptying Replied, post #64 · Practice › Interactions · 19 Jul 2026 · 0 likes SGLT2 inhibitors: frequently co-administered and relevant to renal and cardiovascular discussion, not to interactions. There is no pharmacokinetic interaction of…
-
[2026 update] Detection wavelength and why 214 nm and 280 nm disagree Replied, post #49 · Analytics › HPLC & UHPLC · 19 Jul 2026 · 0 likes Worth separating two things that post #45 runs together. If two laboratories disagree by more than two or three percentage points, work through method, integration,…
-
Journal club: LEADER as the historical anchor Replied, post #106 · Evidence › Journal club · 18 Jul 2026 · 2 likes Reframing LEADER slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it happen", yes. If it is "how…
-
Research-use-only status: what it means legally and practically Replied, post #77 · Compounds › Other compounds · 18 Jul 2026 · 0 likes Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its…
-
Revisiting: Liver enzymes drifting down and what that usually means Replied, post #55 · Clinical › Bloodwork · 11 Jul 2026 · 26 likes Worth separating two things that post #51 runs together. Sample handling before analysis affects several analytes, and a haemolysed sample produces predictable…
-
How shortages have affected compounding permissions Replied, post #28 · Access › Shortages · 10 Jul 2026 · 32 likes Both are useful and different. The notice tells you the national position; the account tells you what is happening on the ground. Caveat: everything above assumes the…
-
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction Replied, post #28 · Compounds › Retatrutide · 9 Jul 2026 · 0 likes Post #27 is right about the mechanism and I think understates the practical bit. Retatrutide is investigational. Anything obtained outside a trial is by definition…
-
Preservatives: function, testing, and limits — one year on Replied, post #29 · Pharmacology › Formulation chemistry · 5 Jul 2026 · 0 likes Sterility and stability are separate properties requiring separate controls. A preservative addresses one of them and nothing about the other. I have kept the units in…
-
Journal club: what we got wrong in an earlier session Replied, post #44 · Evidence › Journal club · 1 Jul 2026 · 12 likes That matches what I have seen, for whatever a single anecdote is worth.